Key result
Early post-AMI SGLT2 inhibitors cut first HF hospitalization or HF death by ~22%.
Why the study?
Preventing adverse left ventricular remodeling and heart failure remains a key challenge after acute myocardial infarction, motivating a systematic evaluation of early SGLT2 inhibitor initiation in this population.
Does early initiation of SGLT2 inhibitors reduce all-cause mortality, cardiovascular mortality, and heart failure hospitalizations, and improve left ventricular remodeling compared to placebo or standard care in adult patients following an acute myocardial infarction?
Systematic Review
Does early initiation of SGLT2 inhibitors reduce all-cause mortality, cardiovascular mortality, and heart failure hospitalizations, and improve left ventricular remodeling compared to placebo or standard care in adult patients following an acute myocardial infarction?
Early initiation of SGLT2 inhibitors following acute myocardial infarction is safe and significantly reduces heart failure hospitalizations, though it does not consistently reduce all-cause mortality.
Answers are grounded in this paper and cite their sources.
Supports early post-AMI SGLT2 inhibitor initiation to reduce HF events; confirms and extends landmark RCT evidence.
Background: Preventing adverse left ventricular remodeling and heart failure (HF) remains a key challenge after acute myocardial infarction (AMI). This systematic review evaluated the efficacy and safety of early SGLT2 inhibitor initiation in patients with AMI. Aim: To systematically evaluate the clinical efficacy and safety of SGLT2 inhibitors initiated early after AMI, focusing on heart failure outcomes, mortality, echocardiographic markers of ventricular remodeling, and treatment-related adverse events Materials and methods: A systematic PubMed search identified 30 eligible studies (including 24 randomized controlled trials and post-hoc analyses) that evaluated SGLT2 inhibitors versus placebo or standard care in adults post-AMI patients. Key outcomes included mortality, HF hospitalizations, echocardiographic parameters, and adverse events Results: SGLT2 inhibitors (predominantly empagliflozin 10 mg or dapagliflozin 10 mg daily) were typically initiated within 72 h to 14 days post-MI. While all-cause mortality was comparable to that of placebo across the included studies, SGLT2 inhibitors significantly reduced HF-related endpoints. Landmark evidence (EMPACT-MI) demonstrated a 22% reduction in first HF hospitalization or HF death (HR 0.78; 95% CI 0.62–0.98; P=0.031) and a 31% reduction in total cumulative HF events (RR 0.69; 95% CI 0.51–0.93; P=0.015), irrespective of baseline diabetes or chronic kidney disease status. Most trials also showed favorable impacts on left ventricular remodeling parameters (LVEF and GLS). The therapy exhibited high tolerability, with severe adverse events (ketoacidosis, hypoglycemia, and renal impairment) occurring in <0.1% of patients, similar to the placebo. Conclusion: Early post-AMI initiation of SGLT2 inhibitors is safe and significantly mitigates the risk of HF hospitalization and cumulative adverse cardiac events, supporting their integration into post-infarction therapeutic regimens.
No takes yet. Share an insight, caveat, or question.
Sokołowski et al. (2026) conducted a systematic review in Acute myocardial infarction. SGLT2 inhibitors (predominantly empagliflozin or dapagliflozin) vs. Placebo or standard care was evaluated on First heart failure hospitalization or heart failure-related death (landmark EMPACT-MI analysis) (HR 0.78, 95% CI 0.62–0.98, p=0.031). Early post-AMI SGLT2 inhibitor initiation reduced first HF hospitalization or HF death by 22% and total HF events by 31% without affecting all-cause mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: